Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 2, 2000, Pages 199-200

  Bonnet, Fabrice ^a   Savès, Marianne ^b   Droz, Cécile ^b   Peuchant, Evelyne ^a   Chêne, Geneviève ^b   Beylot, Jacques ^a   Morlat, Philippe ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ATHEROGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LETTER; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034298751     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200010010-00017     Document Type: Letter

References (5)

1. Lipids, lipoproteins, triglycerides clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
2. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
3. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
4. Severe premature coronary artery disease with protease inhibitors
5. Vascular complications associated with use of HIV protease inhibitors